Clinical response by initial treatment
| Response . | POM + DEX (n = 39) . | POM + DEX + IXA (n = 38) . | P value . |
|---|---|---|---|
| ORR, all patients (95% CI) | 43.6% (27.8-60.4) | 63.2% (46.0-78.2) | P = .1113∗ |
| ≥VGPR rate, all patients (95% CI) | 5.1% (0.6-17.3) | 28.9% (15.4-45.9) | P = .0063∗ |
| ORR, standard-risk cytogenetics (95% CI) | 41.7% (22.1-63.4) | 73.7% (48.8-90.9) | |
| ≥VGPR rate, standard-risk cytogenetics (95% CI) | 4.2% (0.1-21.1) | 36.8% (16.3-61.6) | |
| ORR, high-risk cytogenetics (95% CI) | 46.7% (21.3-73.4) | 52.6% (28.9-75.6) | |
| ≥VGPR rate, high-risk cytogenetics (95% CI) | 6.7% (0.2-32.0) | 21.1% (6.1-45.6) | |
| Median duration of ≥ PR | 12.3 mo | 23.7 mo | P = .1727† |
| Response . | POM + DEX (n = 39) . | POM + DEX + IXA (n = 38) . | P value . |
|---|---|---|---|
| ORR, all patients (95% CI) | 43.6% (27.8-60.4) | 63.2% (46.0-78.2) | P = .1113∗ |
| ≥VGPR rate, all patients (95% CI) | 5.1% (0.6-17.3) | 28.9% (15.4-45.9) | P = .0063∗ |
| ORR, standard-risk cytogenetics (95% CI) | 41.7% (22.1-63.4) | 73.7% (48.8-90.9) | |
| ≥VGPR rate, standard-risk cytogenetics (95% CI) | 4.2% (0.1-21.1) | 36.8% (16.3-61.6) | |
| ORR, high-risk cytogenetics (95% CI) | 46.7% (21.3-73.4) | 52.6% (28.9-75.6) | |
| ≥VGPR rate, high-risk cytogenetics (95% CI) | 6.7% (0.2-32.0) | 21.1% (6.1-45.6) | |
| Median duration of ≥ PR | 12.3 mo | 23.7 mo | P = .1727† |